DDInter898 DDInter1376
Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light chains of 213 amino acids each.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Ibritumomab tiuxetan {u} may cause a minor interaction that can limit clinical effects when taken with {v} Capsicum
Ibritumomab tiuxetan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alefacept
Ibritumomab tiuxetan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Palifermin
Ibritumomab tiuxetan {u} may lead to a major life threatening interaction when taken with {v} Antithrombin Alfa
Ibritumomab tiuxetan {u} may lead to a major life threatening interaction when taken with {v} Abciximab
Ibritumomab tiuxetan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v} Ketorolac
Ibritumomab tiuxetan may cause a minor interaction that can limit clinical effects when taken with Capsicum
Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Alefacept
Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Palifermin
Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Antithrombin Alfa
Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Abciximab
Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Ketorolac and Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Ketorolac